A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBA
What they do
ShiraTronics designs an active implantable medical device system that delivers electrical stimulation to specific cranial nerves. The system is designed for patients suffering from severe, drug-resistant chronic migraines who require consistent therapeutic intervention.
The record
- Vertical
- Medical Devices
- Sub-segment
- Neuromodulation therapy
- Product type
- Device
- Stage
- Series B
- Headquarters
- Brooklyn Park, USA
- Region
- North America
- Founded
- 2018
- Total funding
- $99M raised
Notable investors: USVP, Ampeak Capital, Aperion Biologics.
Also in Medical Devices
Related on The Signal
Dr. Dereck Mush, MD, MBA
Next-Gen Neurotechnologies: Graphene Electrodes and Magnetic Surgical Robotics in Deep Brain Neuromodulation
Dr. Dereck Mush, MD, MBA
Industrializing Cell and Gene Therapy: The Economics of Multiply Labs' $75M Robotic Cleanroom Clusters
Dr. Dereck Mush, MD, MBA
CDMOs race to add capacity as cell and gene therapy demand outpaces supply
Dr. Dereck Mush, MD, MBA